Saghmos Therapeutics Announces Notice of Allowance for Second US Patent for Phase 3-Ready Cardiorenal Metabolic Modulator ST-62516

Patent has broad claims for the Reduction of Acute Kidney Injury and Major Adverse Cardiac and Kidney Events in Patients with Chronic Kidney Disease

Provides exclusivity through 2037

Saghmos Therapeutics, Inc. (Saghmos), a privately held biopharmaceutical company, announced a Notice of Allowance for a second US patent for its Phase 3-ready product, ST-62516 (trimetazidine), a cardiorenal metabolic modulator. The patent will provide exclusivity through 2037, with broad claims for the reduction of acute kidney injury and major adverse cardiac and kidney events in patients with chronic kidney disease (CKD) undergoing contrast procedures.

"We are very pleased to announce the Notice of Allowance for our second patent, which will enhance the long-term value of ST-62516. Saghmos continues to build its intellectual property estate,” commented Anna Kazanchyan, MD, Founder and CEO of Saghmos Therapeutics.

Saghmos is developing ST-62516 to reduce the risk of Acute Kidney Injury (AKI) and Major Adverse Cardiac and Kidney Events (MACKE) after contrast procedures such as percutaneous coronary intervention (PCI). Saghmos’ IND for ST-62516 was cleared by the FDA in July 2023. In the Phase 3 study, the drug will be administered to patients for 90 days, starting just prior to the PCI procedure.

Over one million PCI procedures are performed annually in the US in patients with unstable angina (heart attack). About half of these patients have comorbidities such as heart disease, chronic kidney disease, diabetes, or are aged >75, all of which impact the safety of PCI. In addition, several procedure-related factors could lead to AKI and MACKE. This is a major unmet medical need with no FDA-approved drugs available to prevent or treat AKI and MACKE. ST-62516 could benefit all PCI patients, not just those with comorbidities, to reduce the threat of AKI and MACKE after PCI.

About Saghmos Therapeutics

Saghmos Therapeutics is developing ST-62516 (trimetazidine) to reduce the risk of cardiorenal complications after PCI. The company has an issued US patent (Patent number 11,123,345) for the prevention and treatment of acute kidney injury after contrast procedures. Saghmos recently announced the appointment of Fred Hassan as Chairman of the Board of Directors.

Forward looking statements

This press release contains forward-looking statements, pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements contained in this press release include, but are not limited to, statements regarding Saghmos Therapeutics’ business, intellectual property, clinical and regulatory plans, commercial potential, and the value and benefits of ST-62516. In any forward-looking statement in which Saghmos expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Saghmos’ actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources, uncertainties and changes related to the law and regulatory process, and general changes in the economic environment. These forward looking statements are based on our current expectations. Saghmos does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240206992124/en/